viewValiRx PLC

ValiRx outlines next step for prostate cancer drug

VAL201 has been shown to be safe and well tolerated during phase I/II trials and, crucially, there was “primary evidence” of the drug’s activity in patients

drugs being tested
The company has been conducting early-stage clinical trials of its lead drug

ValiRx Plc (LON:VAL) said the dose ranging study of its lead drug continued as it outlined potential next steps.

VAL201 is being used to treat men with prostate cancer drug. It is also being developed to combat hormone-induced unregulated growth including endometriosis.

It has been shown to be safe and well tolerated during phase I/II trials and, crucially, there was “primary evidence” of the drug’s activity in prostate cancer. The company has said previously that results from the trial are expected at the end of the first-half, which will be followed by data analysis and the publication of the full findings of the clinical assessment.

In an update alongside its full-year results, ValiRx also said it would either out-licence VAL201 to a major pharmaceutical company or proceed to a phase llb study once dose-ranging is complete.

What's next?

In the prelims, which were largely a summary of the work carried out last year, it said it was aiming to get VAL301, a treatment of the gynaecological condition, endometriosis, into the clinic this year.

However its plans would be “dependant on funding and regulatory clearance”, it added.

ValiRx is assessing potential commercial or academic tie-ups for VAL101, which has been shown to induce programmed cell death.

The results showed ValiRx made a loss of £4.3mln last year while raising £3.7mln by issuing new shares.

At the end December last year it had cash of £372,872. It is currently in financing discussions.

Quick facts: ValiRx PLC

Price: 0.105 GBX

Market: AIM
Market Cap: £1.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read